Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Reports Interim Data Analysis Showed That Its Ino-5150 Cancer Immunotherapy Product

216

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares eased down after opening to traded at $6.03 as Inovio Pharmaceuticals, Inc. (INO) reported that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent prostate cancer.

The immunology results demonstrate that INO-5150 treatment as a monotherapy generated prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA) specific T cell responses in peripheral blood in 60% (35/58) of the subjects. Moreover, patients with specific CD8+ T cell responses experienced dampening in the rise of PSA and important increases in PSA Doubling Times (PSADT). PSA is a prostate cancer associated biomarker and positive changes on PSA levels could signal INO-5150’s potential positive impact on the treatment of prostate cancer. These results were presented as a poster discussion on September 10th at the 2017 European Society of Medical Oncology (ESMO) meeting in Madrid, Spain. Dr. Neil Shore, MD, Medical Oncologist at Urologic Associates of North Carolina, and the principal investigator of this study said, “Immunotherapy is an exciting new approach being evaluated for the treatment of many cancers including prostate cancer, where a small subset of patients have been shown to demonstrate clinical benefit from such therapy in the form of checkpoint inhibitors. Our study provides encouraging immunologic and clinical data that Inovio’s immunotherapy product can generate antigen-specific CD8+ killer T cell responses in the blood and link such responses to PSA changes in prostate cancer patients. Our results suggest that further evaluation of this product in prostate cancer patients should be explored.”

INO is ahead its 52-week low with 14.20%and going down from its 52-week high price with -38.84%. The company’s shares performance for the last one month was 9.84% and 1.52% in the previous week.

Nuance Communications, Inc. (NASDAQ:NUAN) swings ardently in active trading session, it rises up of 2.25% to close at $15.93. Nuance Communications, Inc.(NASDAQ:NUAN) reported that its Dragon Drive connected car platform will power all conversational, connected services in the new Audi A8, with additional Audi models to follow.

Dragon Drive utilizes cloud-based speech recognition, natural language understanding, and text-to-speech (TTS) to create a truly conversational automotive assistant that listens, understands and responds to drivers.

Dragon Drive will provide Audi A8 drivers with a fully customized, conversational system that is deeply integrated with the Audi vehicle, giving them voice-controlled access to all connected services, including weather, points of interest and addresses, parking, gas stations, as well as calendars and notes. The platform also provides access to embedded services like music and navigation and in-car functions such as air conditioning. Dragon Drive can interact with drivers through automotive-grade signal enhancement and acoustics innovation combined with hybrid embedded-cloud speech recognition and natural language understanding, as well as text-to-speech. “The Audi A8 is designed to provide a luxurious, highly automated driving experience, and that includes a truly intuitive automotive assistant that can engage in natural conversation,” said Martin Deinhard, Head Of Development Connected Services & Speech Assistant, Audi. “Nuance’s Dragon Drive is the ideal platform for the delightful user experience reflecting our brand.”

The stock price of firm is moving up from its 20 days moving average with 0.10% and remote isolated negatively from 50 days moving average with -4.58%.

Moving toward the volatility measures, the price volatility of stock was 1.71% for a week and 1.87% for a month as well as price volatility’s Average True Range for 14 days was 0.34. The beta, which indicates risk in relegation to the market, remained 0.66. The firm past twelve months price to sales ratio was 2.35 and price to cash ratio remained 5.35. As far as the returns are concern, the return on equity was recorded as -3.50% and return on investment was 2.80% while its return on asset stayed at -1.10%.

LEAVE A REPLY

Please enter your comment!
Please enter your name here